Personalized Diagnostics Is Dynamic Area of IVD Sector

Diagnostic tests that can direct a therapy to a specific patient, or segment of the population, to improve outcomes and lower costs, are experiencing faster sales growth.

A detailed account by Kalorama Information (New York, NY, USA), the healthcare market research publisher, tracks sales of personalized medicine tests, reporting growth falling between 7% and 38% per year, compared with the more moderate 2%-6% growth of in vitro diagnostics (IVD) generally.

Personalized tests such as fluorescent in situ hybridization (FISH) for cancer screening, CYP450 tests for psychiatric therapy, individual microbiologic assessments to treat infectious disease, and tissue transplant typing, rose to USD 28.1 billion in 2011.

Kalorama's market estimate covers tests that can also provide therapy decision-making information that is tailored to the individual, which falls into four categories: tests that identify a population in which the therapeutic product will achieve greater (or little) effectiveness, tests that identify a patient population that should not receive a particular therapeutic product, tests that identify the characteristics of a disease, and tests that are the basis for selecting a safe and efficacious therapeutic dose.

In the full study, Kalorama Information defines the current opportunity and realistic future potential of personalized medicine in clinical testing. More...